I agree that this site is using cookies. You can find further informations here.
X
Jakubowiak, A
309  results:
Search for persons X
?
1

High daratumumab detection rate in multiple myeloma patient..:

Barnidge, D. ; Sakrikar, D. ; Kubicki, T....
Clinica Chimica Acta.  558 (2024)  - p. 118429 , 2024
Link: https://doi.org/10.1016/..
 
?
2

P23 EMAGINE/CARTITUDE-6: A RANDOMIZED PHASE 3 STUDY OF DVRD..:

Broijl, A. ; San-Miguel, J. ; Suzuki, K....
HemaSphere.  7 (2023)  S2 - p. 22-23 , 2023
Link: https://doi.org/10.1097/..
 
?
3

P1446: PHASE I STUDY DATA UPDATE OF PHE885, A FULLY HUMAN B..:

Sperling, A. S. ; Nikiforow, S. ; Derman, B....
HemaSphere.  6 (2022)  - p. 1329-1330 , 2022
Link: https://doi.org/10.1097/..
 
?
4

P971: ADJUSTED COMPARISON OF PATIENT REPORTED OUTCOMES FROM..:

Weisel, K. ; Mateos, M.-V. ; Vincent, L....
HemaSphere.  6 (2022)  - p. 861-862 , 2022
Link: https://doi.org/10.1097/..
 
?
5

P961: CILTACABTAGENE AUTOLEUCEL, A BCMA-DIRECTED CAR-T CELL..:

Lin, Y. ; Martin, T. ; Berdeja, J. G....
HemaSphere.  6 (2022)  - p. 851-852 , 2022
Link: https://doi.org/10.1097/..
 
?
6

P934: DARATUMUMAB + LENALIDOMIDE, BORTEZOMIB, AND DEXAMETHA..:

Rodriguez, C. ; Kaufman, J. L. ; Laubach, J....
HemaSphere.  6 (2022)  - p. 824-825 , 2022
Link: https://doi.org/10.1097/..
 
?
7

P847: MRD BY MASS SPECTROMETRY IN PERIPHERAL BLOOD AND NEXT..:

Derman, B. ; Rosenblatt, J. ; Avigan, D....
HemaSphere.  6 (2022)  - p. 741-742 , 2022
Link: https://doi.org/10.1097/..
 
?
8

P897: UPDATED RESULTS FROM THE ONGOING PHASE 1 STUDY OF ELR..:

Dalovisio, A. ; Bahlis, N. ; Raje, N....
HemaSphere.  6 (2022)  - p. 788-789 , 2022
Link: https://doi.org/10.1097/..
 
?
9

UPDATED RESULTS FROM THE CARTITUDE-1 STUDY OF CILTACABTAGEN..:

Usmani, SZ ; Berdeja, JG ; Jakubowiak, A...
Hematology, Transfusion and Cell Therapy.  43 (2021)  - p. S272 , 2021
Link: https://doi.org/10.1016/..
 
?
10

INCIDENCE, MITIGATION, AND MANAGEMENT OF NEUROLOGIC ADVERSE..:

Einsele, H ; Parekh, S ; Madduri, D...
Hematology, Transfusion and Cell Therapy.  43 (2021)  - p. S263-S264 , 2021
Link: https://doi.org/10.1016/..
 
?
11

EFFICACY AND SAFETY OF ELRANATAMAB (PF-06863135), A B-CELL ..:

Solh, M ; Bahlis, NJ ; Raje, NS...
Hematology, Transfusion and Cell Therapy.  43 (2021)  - p. S195-S196 , 2021
Link: https://doi.org/10.1016/..
 
?
12

UPDATE OF CARTITUDE-1: A PHASE 1B/2 STUDY OF JNJ-68284528 (..:

Berdeja, J.G. ; Madduri, D. ; Usmani, S.Z....
Hematology, Transfusion and Cell Therapy.  42 (2020)  - p. 279-280 , 2020
Link: https://doi.org/10.1016/..
 
?
13

Carfilzomib–lenalidomide–dexamethasone vs lenalidomide–dexa..:

Dimopoulos, M A ; Stewart, A K ; Masszi, T...
Blood Cancer Journal.  7 (2017)  4 - p. e554-e554 , 2017
Link: https://doi.org/10.1038/..
 
?
14

Anti-myeloma activity of MELK inhibitor OTS167: effects on ..:

Stefka, A T ; Park, J-H ; Matsuo, Y...
Blood Cancer Journal.  6 (2016)  8 - p. e460-e460 , 2016
Link: https://doi.org/10.1038/..
 
?
15

Carfilzomib (CFZ, Kyprolis®), lenalidomide (LEN, Revlimid®)..:

Jakubowiak, A.J. ; Griffith, K. ; Jasielec, J.K....
Clinical Lymphoma Myeloma and Leukemia.  15 (2015)  - p. e42 , 2015
Link: https://doi.org/10.1016/..
 
1-15